Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
Galectin Therapeutics Q3 EPS $(0.04) Beats $(0.05) Estimate
Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Galectin Therapeutics Converts ~$105.8M Of Debt Into ~34.4M Shares At Blended Average Conversion Price Of ~$3.07 Per Share
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Galectin Therapeutics Announces Positive Feedback From Recent In Person Type C Meeting With FDA For Its Belapectin To Treat Patients With Metabolic Dysfunction-associated Steatohepatitis Cirrhosis, Portal Hypertension
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.